• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PPD

    PPD, Inc.

    Subscribe to $PPD
    $PPD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: ppd.com

    Peers

    $ICLR
    $MEDP

    Recent Analyst Ratings for PPD, Inc.

    DatePrice TargetRatingAnalyst
    8/5/2021$47.50Neutral
    Credit Suisse
    See more ratings

    PPD, Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse resumed coverage on PPD with a new price target

      Credit Suisse resumed coverage of PPD with a rating of Neutral and set a new price target of $47.50

      8/5/21 6:25:35 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by JP Morgan with a new price target

      JP Morgan downgraded PPD from Overweight to Neutral and set a new price target of $48.00

      4/28/21 10:25:55 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Jefferies

      Jefferies downgraded PPD from Buy to Hold

      4/20/21 8:11:33 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Credit Suisse with a new price target

      Credit Suisse downgraded PPD from Outperform to Neutral and set a new price target of $47.50 from $42.00 previously

      4/19/21 7:29:36 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Evercore ISI Group with a new price target

      Evercore ISI Group downgraded PPD from Outperform to In-Line and set a new price target of $47.50 from $46.00 previously

      4/16/21 12:11:25 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Truist Securities

      Truist Securities downgraded PPD from Buy to Hold

      4/16/21 8:46:49 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded PPD from Buy to Hold and set a new price target of $47.00 from $39.00 previously

      4/16/21 8:37:10 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by William Blair

      William Blair downgraded PPD from Outperform to Market Perform

      4/16/21 7:19:34 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Keybanc with a new price target

      Keybanc downgraded PPD from Overweight to Sector Weight and set a new price target of $40.00

      4/16/21 6:15:39 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Baird with a new price target

      Baird downgraded PPD from Outperform to Neutral and set a new price target of $48.00

      4/15/21 11:58:06 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    PPD, Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/9/21 5:14:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 5:05:14 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:53:26 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Johnston David Michael returned $1,681,832 worth of shares to the company (60,929 units at $27.60) and was granted 25,522 shares, closing all direct ownership in the company

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:41:49 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Hill Colin returned $775,675 worth of shares to the company (16,330 units at $47.50), closing all direct ownership in the company

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:41:24 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Kaucic Karen returned $398,620 worth of shares to the company (31,496 units at $12.66) and was granted 23,104 shares, closing all direct ownership in the company

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:40:43 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Donovan Glen was granted 8,182 shares and returned $142,500 worth of shares to the company (11,182 units at $12.74), closing all direct ownership in the company

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:40:25 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: James Julia returned $1,019,825 worth of shares to the company (42,334 units at $24.09) and was granted 20,864 shares, closing all direct ownership in the company

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:40:01 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Kindler Jeffrey B returned $5,604,382 worth of shares to the company (117,987 units at $47.50), closing all direct ownership in the company

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:39:34 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Fikry Christopher returned $598,642 worth of shares to the company (35,439 units at $16.89) and was granted 22,836 shares, closing all direct ownership in the company

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:39:15 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    PPD, Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PPD, Inc.

      SC 13G - PPD, Inc. (0001793294) (Subject)

      12/9/21 5:06:56 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/12/21 4:19:09 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/12/21 6:11:58 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/2/21 1:19:06 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    PPD, Inc. SEC Filings

    See more
    • SEC Form 15-12B filed by PPD, Inc.

      15-12B - PPD, Inc. (0001793294) (Filer)

      12/20/21 5:20:22 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PPD, Inc.

      S-8 POS - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:16:02 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:12:04 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 25-NSE filed by PPD, Inc.

      25-NSE - PPD, Inc. (0001793294) (Subject)

      12/8/21 8:39:10 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by PPD, Inc.

      10-Q - PPD, Inc. (0001793294) (Filer)

      10/28/21 4:01:24 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PPD, Inc. (0001793294) (Filer)

      10/27/21 4:09:41 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by PPD, Inc.

      10-Q - PPD, Inc. (0001793294) (Filer)

      7/29/21 4:05:31 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PPD, Inc. (0001793294) (Filer)

      7/28/21 4:06:05 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFR14C filed by PPD, Inc.

      DEFR14C - PPD, Inc. (0001793294) (Filer)

      5/26/21 4:55:35 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFM14C filed by PPD, Inc.

      DEFM14C - PPD, Inc. (0001793294) (Filer)

      5/25/21 4:18:32 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    PPD, Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Saama Appoints Scott Rogers as Company's Chief Financial Officer

      Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the

      2/2/22 8:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

      WALTHAM, Mass., Dec. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (NASDAQ:PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. "We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapi

      12/8/21 8:45:00 AM ET
      $PPD
      $TMO
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Industrial Machinery/Components
      Industrials
    • PPD Named to 'Best Workplaces in Greater China' for Second Consecutive Year

      PPD, Inc. (NASDAQ:PPD) was named one of the "Best Workplaces in Greater China™ 2021" by Great Place to Work® for successfully creating an inclusive workplace experience for employees. PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services in Greater China. This is the second year PPD has received this recognition from Great Place to Work®, a global authority on high-trust, high-performance workplace cultures. "We remain committed to providing a healthy and open work environment for our employees, and this award shows that we continue to be successful in our efforts for yet another year," said D

      12/7/21 9:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD Named 'Best Vaccine CRO of the Year' in Asia-Pacific

      PPD, Inc. (NASDAQ:PPD) was named "Best Vaccine CRO of the Year" at the Asia-Pacific Vaccine Excellence Awards 2021 for its strong presence, extensive experience and quality delivery in the Asia-Pacific (APAC) region. The award recognizes the contract research organization (CRO) operating within Asia that has engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality and safety in vaccine development and manufacturing. PPD accepted the award during a virtual ceremony at the third annual Vaccine World Asia Congress 2021, which attracted hundreds of representatives from Asia's top vaccine and supply chain companies. "This vaccine award furthe

      12/2/21 9:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD Wins Multiple Awards at Clinical Researcher of the Year Competition

      PPD, Inc. (NASDAQ:PPD) earned numerous honors at the 2021 PharmaTimes Clinical Researcher of the Year-The Americas competition. Two PPD teams won gold, one team won silver and another team took home bronze. PPD clinical researchers also won silver and bronze awards in various individual categories. Last month, PPD was named "Clinical Research Company of the Year" at the 2021 PharmaTimes Clinical Researcher of the Year International competition in London. In addition to PPD winning the highest honor, a number of individual PPD clinical researchers also took home top honors in the individual categories during the international competition. "This award demonstrates that PPD's clinical resear

      11/22/21 9:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD Reports Third Quarter and Year-To-Date 2021 Results

      PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021. Highlights Net authorizations growth of 12.7% over third quarter 2020 to $1,352.7 million, resulting in a net book-to-bill ratio of 1.19x on a historical basis Ending backlog growth of 20.3% over third quarter 2020 to $9,492.5 million on a historical basis Revenue of $1,560.8 million, representing growth of 26.5% over third quarter 2020 Net income attributable to common stockholders of $152.9 million, compared to $52.0 million in thirdquarter 2020 Adjusted EBITDA of $280.3 million, compared to $232.6 million in third quarter

      10/27/21 4:10:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Medable Secures $304 Million in Funding at $2.1 Billion Valuation; New Round Co-Led by Blackstone Growth, GSR Ventures and Tiger Global

      Funding Will Help Medable Accelerate Drug Development Through Decentralized Clinical Trials Medable Inc., the leading cloud platform for patient-centered clinical research, today announced $304 million in Series D funding to accelerate global adoption of digital and decentralized clinical trials, enabling ubiquitous access to the latest treatments for every body and every biology. The funding round was co-led by new investors Blackstone Growth and Tiger Global and existing investor GSR Ventures. The round also includes follow-on investment from existing investors Sapphire Ventures and WTI. This is Medable's fourth round of funding in 18 months, bringing total capital raised to $521 millio

      10/26/21 7:37:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD Named Clinical Research Company of the Year for Second Consecutive Year

      PPD, Inc. (NASDAQ:PPD) was named "Clinical Research Company of the Year" at the 2021 PharmaTimes Clinical Researcher of the Year International competition in London. In addition to PPD winning the highest honor, individual PPD clinical researchers won gold and silver in both the Clinical Research Team and Start Up-Singles categories, as well as silver and bronze awards in the Aspiring Clinical Research Associate (CRA) category and bronze in the In-House CRA category. "This is the second year in a row that PPD has won this award, and we are thrilled that our clinical researchers continue to be recognized by PharmaTimes for their talent, work ethic and commitment to this industry year after

      10/19/21 9:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD Announces Third Quarter 2021 Earnings Conference Call

      PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD's website at https://investors.ppd.com. An archived copy of the webcast will be available on the website after the call. In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 5

      10/18/21 4:05:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Society for Clinical Research Sites Names PPD Winner of Prestigious Eagle Award

      PPD, Inc. (NASDAQ:PPD) is the recipient of the 2021 Eagle Award from the Society for Clinical Research Sites (SCRS) for its commitment to advancing clinical research professionalism through strong site partnerships. The award, based on voting by research sites globally, recognizes the contract research organization (CRO) that best exemplifies a site-focused approach to clinical trial management by demonstrating outstanding leadership, professionalism and integrity. "The Eagle Award is one of the most prestigious honors in our industry, and this recognition affirms PPD's ongoing commitment to create and sustain strong relationships with our site partners," said David Johnston, Ph.D., execu

      10/6/21 9:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    PPD, Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Saama Appoints Scott Rogers as Company's Chief Financial Officer

      Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the

      2/2/22 8:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    PPD, Inc. Financials

    Live finance-specific insights

    See more
    • PPD Announces Third Quarter 2021 Earnings Conference Call

      PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD's website at https://investors.ppd.com. An archived copy of the webcast will be available on the website after the call. In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 5

      10/18/21 4:05:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

      CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) f

      11/30/20 6:59:00 AM ET
      $MRNA
      $PPD
      $MCK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Other Pharmaceuticals